BioanalysisVol. 5, No. 15 CommentaryControlling bioanalytical variability: a perennial questManish S Yadav & Pranav S ShrivastavManish S Yadav* Author for correspondenceClinical Research & Bioanalysis, R&D Centre, Alkem Laboratories limited, Taloja, Raigad-410208, Maharashtra, India. Search for more papers by this authorEmail the corresponding author at ysmanish@yahoo.com & Pranav S ShrivastavDepartment of Chemistry, School of Sciences, Gujarat University, Ahmedabad-380009, Gujarat, IndiaSearch for more papers by this authorPublished Online:1 Aug 2013https://doi.org/10.4155/bio.13.134AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: bioanalytical variabilitybiological matrixphospholipids associated matrix interferencereal sampleregulated bioanalysisspiked sampleunidentified co-eluting matrix componentsReferences1 Trufelli H, Palma P, Famiglini G, Cappiello A. An overview of matrix effects in liquid chromatography–mass spectrometry. Mass Spectrom. Rev.30,491–509 (2011).Crossref, Medline, CAS, Google Scholar2 Cappiello A, Famiglini G, Palma P, Pierini E, Termopoli V, Trufelli H. Overcoming matrix effects in liquid chromatography–mass spectrometry. Anal. Chem.80(23),9343–9348 (2008).Crossref, Medline, CAS, Google Scholar3 Stahnke H, Kittlaus S, Kempe G, Hemmerling C, Alder L. The influence of electrospray ion source design on matrix effects. J. Mass Spectrom.47(7),875–84 (2012).Crossref, Medline, CAS, Google Scholar4 Marchi I, Viette V, Badoud F et al. Characterization and classification of matrix effects in biological samples analyses. J. Chromatogr. A1217,4071–4078 (2010).Crossref, Medline, CAS, Google Scholar5 Eeckhaut AV, Lanckmans K, Sarre S, Smolders I, Michotte Y. Validation of bioanalytical LC–MS/MS assays: evaluation of matrix effects. J. Chromatogr. B877,2198–2207 (2009).Crossref, Medline, Google Scholar6 Cote C, Bergeron A, Mess JN. Furtado M, Garofolo F. Matrix effect elimination during LC-MS/MS bioanalytical method development. Bioanalysis1(7),1243–1257 (2009).Link, CAS, Google Scholar7 Chambers E, Wagrowski-Diehl DM, Lu Z, Mazzeo JR. Systematic and comprehensive strategy for reducing matrix effects in LC–MS/MS analyses. J. Chromatogr. B852,22–34 (2007).Crossref, Medline, CAS, Google Scholar8 Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC–MS/MS. Anal. Chem.75,3019–3030 (2003).Crossref, Medline, CAS, Google Scholar9 Bérubé ER, Marie-Pierre Taillon MP, Milton Furtado M, Garofolo F. Impact of sample hemolysis on drug stability in regulated bioanalysis. Bioanalysis3(18),2097–2105 (2011).Link, CAS, Google Scholar10 Xia YQ, Jemal M. Phospholipids in liquid chromatography/mass spectrometry bioanalysis: comparison of three tandem mass spectrometric techniques for monitoring plasma phospholipids, the effect of mobile phase composition on phospholipids elution and the association of phospholipids with matrix effects. Rapid Commun. Mass Spectrom.23,2125–2138 (2009).Crossref, Medline, CAS, Google Scholar11 Jemal M, Ouyang Z, Xia YQ. Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought-out chromatography. Biomed. Chromatogr.24,2–19 (2010).Crossref, Medline, CAS, Google Scholar12 Xu X, Mei H, Wang S et al. A study of common discovery dosing formulation components and their potential for causing time-dependent matrix effects in high-performance liquid chromatography tandem mass spectrometry assays. Rapid Commun. Mass Spectrom.19,2643–2650 (2005).Crossref, Medline, CAS, Google Scholar13 James CA, Breda M, Frigerio E. Bioanalytical method validation: a risk-based approach? J. Pharm. Biomed. Anal.35,887–893 (2004).Crossref, Medline, CAS, Google Scholar14 Fabio Garofolo F, Bergeron A, Savoie N. How to manage having no incurred sample reanalysis evaluation failures. Bioanalysis3(9),935–938 (2011).Link, Google Scholar15 Dicaire C, Bérubé ER, Dumont I, Furtado M, Garofolo F. Impact of oxcarbazepine sulfate metabolite on incurred sample reanalysis and quantification of oxcarbazepine. Bioanalysis3(9),973–982 (2011).Link, CAS, Google Scholar16 Yu H, Cornett C, Larsen J, Hansen SH. Reaction between drug substances and pharmaceutical excipients: Formation of esters between cetirizine and polyols. J. Pharm. Biomed. Anal.53,745–750 (2010).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByImpact of electrospray ion source platforms on matrix effect due to plasma phospholipids in the determination of rivastigmine by LC–MS/MSVikas Trivedi, Vivek Upadhyay, Manish Yadav, Pranav S Shrivastav & Mallika Sanyal10 November 2014 | Bioanalysis, Vol. 6, No. 17 Vol. 5, No. 15 Follow us on social media for the latest updates Metrics Downloaded 170 times History Published online 1 August 2013 Published in print August 2013 Information© Future Science LtdKeywordsbioanalytical variabilitybiological matrixphospholipids associated matrix interferencereal sampleregulated bioanalysisspiked sampleunidentified co-eluting matrix componentsFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download